Cancer stem cells: therapeutic targets

author

  • Mahdi Habibi-Anbouhi National Cell Bank, Pasteur Institute of Iran, 12-Farvardin St., Pasteur St., Tehran, Iran.
Abstract:

Cancer stem cells (CSCs) have been identified as rare cellular populations in many cancers, including leukemia and solid tumors. This minor subpopulation of cancerous cells is immortal tumor-initiating cells which thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug/radiation resistance. Low proliferative rate, high self-renewing capacity, differentiation into actively proliferating tumor cells, resistance to chemotherapy or radiation, expression of the stem cell surface marker, poorly immune-regulated and highly metastasize are distinct characteristics of CSCs in comparison with normal stem cells. Up to now, some therapeutic strategies that selectively target CSCs have been identified and in some cases have been evaluated in clinical studies. The crucial regulating pathways in addition of surface biomarkers and also niche of cancer stem cells are considered as novel CSC-targeted therapeutic strategies aiming to eradicate malignancies. Keywords: Cancer Stem Cells (CSCs), CSCs Targeting.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

cancer stem cells: therapeutic targets

cancer stem cells (cscs) have been identified as rare cellular populations in many cancers, including leukemia and solid tumors. this minor subpopulation of cancerous cells is immortal tumor-initiating cells which thought to be responsible for cancer initiation, progression, metastasis, recurrence and drug/radiation resistance. low proliferative rate, high self-renewing capacity, differentiatio...

full text

New therapeutic targets in ovarian cancer stem cells

Whether classifi ed as “tumor-initiating” cells, “cancer stem-like” cells or simply “cancer stem cells” (CSCs), this small population of highly undiff erentiated and slow cycling cells is implicated in early molecular events linked to cancer development as well as in tumor progression, recurrence, and development of chemotherapy resistance (1). During the last decade an increasing amount of sci...

full text

Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets.

Elucidating the origin of and dynamic interrelationship between intratumoral cell subpopulations has clear clinical significance in helping to understand the cellular basis of treatment response, therapeutic resistance, and tumor relapse. Cancer stem cells (CSC), together with clonal evolution driven by genetic alterations, generate cancer cell heterogeneity commonly observed in clinical sample...

full text

The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide malignancy and the third leading cause of cancer death in patients. Several studies demonstrated that hepatic cancer stem cells (HCSCs), also called tumor-initiating cells, are involved in regulation of HCC initiation, tumor progression, metastasis development, and drug resistance. Despite the extensive research, the under...

full text

Cancer Stem Cells Therapeutic Target Database: The First Comprehensive Database for Therapeutic Targets of Cancer Stem Cells

Cancer stem cells (CSCs) are a subpopulation of tumor cells that have strong self-renewal capabilities and may contribute to the failure of conventional cancer therapies. Hence, therapeutics homing in on CSCs represent a novel and promising approach that may eradicate malignant tumors. However, the lack of information on validated targets of CSCs has greatly hindered the development of CSC-dire...

full text

Stem cells as potential therapeutic targets for inflammatory bowel disease.

The incidence and prevalence of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD), are rising. According to some estimates >1 million new cases of IBD arise in the United States annually. The conventional therapies available for IBD range from anti-inflammatory drugs to immunosuppressive agents, but these therapies generally fail to achieve satisfac...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue 2.3

pages  46- 46

publication date 2014-05-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023